Background (original) (raw)
Related papers
Annals of King Edward Medical University, 2014
Background Iron deficiency of anemia (IDA) is defined as reduced number of red blood cells, and / or reduced concentration hemoglobin (Hb) due to deficiency of iron. Treatment involves dietary modifications and inorganic iron salt supplements like ferrous sulfate (FS) or Iron polymaltose complex (IPC). The decision to select either drug rests on therapeutic efficacy, untoward side effects; cost of complete course, patient's compliance and discretion of physician. Both drugs can be prescribed in oral form. This study aimed at comparing the efficacy of two iron preparations (ferrous sulphate and iron polymaltose complex salts) in childhood iron deficiency anemia. Objective To compare the efficacy of Ferrous Sulphate and Iron Polymaltose Complex salts in the treatment of childhood Iron Deficiency Anemia.
Background Iron deficiency of anemia (IDA) is defined as reduced number of red blood cells, and / or reduced concentration hemoglobin (Hb) due to deficiency of iron. Treatment involves dietary modifications and inorganic iron salt supplements like ferrous sulfate (FS) or Iron polymaltose complex (IPC). The decision to select either drug rests on therapeutic efficacy, untoward side effects; cost of complete course, patient's compliance and discretion of physician. Both drugs can be prescribed in oral form. This study aimed at comparing the efficacy of two iron preparations (ferrous sulphate and iron polymaltose complex salts) in childhood iron deficiency anemia. Objective To compare the efficacy of Ferrous Sulphate and Iron Polymaltose Complex salts in the treatment of childhood Iron Deficiency Anemia. ____________________________________ Methodology This randomized controlled trial was conducted at Department of Pediatric Medicine Unit-II Mayo Hospital, Lahore, for a period of 6...
The Professional Medical Journal, 2018
To compare the efficacy of Ferrous sulfate with iron polymaltose complex in treatment of iron deficiency anemia in children in terms of rise in hemoglobin. Study design: Randomized clinical trial. Setting: Department of Paediatric Medicine Unit I Allied Hospital Faisalabad. Study duration: 6 months. Methodology: All the children of age group 6 month to 12year with hemoglobin level <10g/dl, MCV<70fl corrected for age, MCHC<32%, serum ferritin<8µg/l were included. All other cases of anemia other than iron deficiency anemia such as thalassemia, sickle cell anemia, lead poisoning etc, patients with severe anemia (hb≤6g/dl) because they need blood transfusion to correct anemia, those with decompensated heart failure or acute infection were excluded. After enrolment patients were randomly divided into two groups by lottery method. Group A, patients were given ferrous sulphate. Group B, patients were given iron polymaltose complex (IPC). Both iron preparations were given in the dose of 5mg/kg/day of elemental iron in three divided dosage 30 minutes before meals. Patients were assessed at one month interval after the start of treatment and hemoglobin was checked at follow up visit by taking 2cc blood. Results: Sixty children were studied. Mean age was 2.5 ± 5.1 years, range 7 months to 12 years with 32 girls, 28 boys. The patients were evenly distributed between the two treatment groups (IPC, n = 30, 50%; ferrous sulfate, n = 30, 50%). All erythrocyte-related hematologic parameters after one month treatment showed a significant improvement from baseline with both treatments. A significant improvement in Hb was observed after one month treatment in the IPC group 9.5 ± 1.1g/dL to 10.6 ±1.0 g/dL and the ferrous sulfate group 9.4 ± 1.6 g/dL to 11.2 ± 0.9 g/dL which was statistically significant. Conclusion: From this randomized study, it is concluded that both ferrous sulphate and iron polymaltose complex have equal efficacy in treatment of iron deficiency anemia
Preventive strategy to control iron deficiency anemia in children and adults
JPMA. The Journal of the Pakistan Medical Association, 2003
To compare improvement in hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin and ferritin levels in children aged 5-10 years and women of reproductive age (15-45) supplemented with daily oral and once weekly with single and double dose of ferrous sulphate. Twenty children received 200 mg ferrous sulfate daily and 20 received the same dose once weekly for two months. Ten women received 300 mg ferrous sulfate daily, 10 received the same dose once weekly while 10 received 600 mg of ferrous sulfate once weekly for one month. All parameters improved significantly in children who received 200 mg ferrous sulfate daily and weekly. Similarly, the parameters improved significantly in women who received 300 mg of ferrous sulfate daily and 600 mg of ferrous sulfate weekly. Weekly supplementation of iron is far better in controlling iron deficiency anemia due to cost effectiveness and better compliance.
Sao Paulo Medical Journal, 2008
CONTEXT AND OBJECTIVE: Low compliance among mothers regarding the treatment of anemic children using daily doses of ferrous sulfate administered at home has been reported. This study aimed to establish the effectiveness of weekly doses administered by mothers at home compared with weekly supplements administered directly by healthcare professionals, to reduce the prevalence of anemia. DESIGN AND SETTING: This was a randomized clinical trial at a public healthcare clinic in São José do Rio Preto, Brazil. METHODS: This iron supplementation study was carried out using two intervention groups. The sample population was 130 infants, randomly allocated to two groups of 65 children. All of them received 12 weekly doses of 25 mg of elemental iron, administered either in the public healthcare clinic or at their homes. RESULTS: Treatment compliance was shown in both groups. The prevalence of anemia among all of the children was 75% at the beginning of supplementation and 46.3% at the end of t...
Current Pediatric Reviews, 2018
Background: Iron Deficiency Anemia (IDA) is a major public health problem worldwide. Iron Bisglycinate Chelate (FeBC) and polymaltose iron (FeP) are used for the treatment of IDA and exhibit good tolerability with a low incidence of adverse effects. However, these compounds have important differences in their structures and bioavailability. Objective: To compare the efficacy of oral supplementation with FeBC and FeP in anemic children. Methods: In this double-blind study, children aged 1 to 13 years who were diagnosed with IDA were randomly divided into two groups: i) FeBC, supplemented with iron bisglycinate chelate, and ii) FeP, supplemented with polymaltose iron (3.0 mg iron/kg body weight/day for 45 days for both groups). Results: Both treatments resulted in significant increases in hemoglobin levels, Mean Corpuscular Volume (MCV) and Cell Distribution Width (RDW) and in a reduction of transferrin levels, relative to initial values. However, only FeBC treatment significantly increased ferritin and Mean Corpuscular Hemoglobin (MCH) levels. A significant negative correlation was observed between the increase in ferritin and initial hemoglobin levels in the FeBC group, indicating that the absorption of FeBC is regulated by the body iron demand. Conclusion: These results provide preliminary evidence to suggest a greater efficacy of FeBC than FeP in increasing iron stores.
Research Square (Research Square), 2024
Background: The World Health Organization recommends universal iron supplementation for children aged 6-23 months in countries where anaemia is seen in over 40% of the population. Conventional ferrous salts have low efficacy due to low oral absorption in children with inflammation. Haem iron is more bioavailable and its absorption may not be decreased by inflammation. This study aims to compare daily supplementation with haem iron versus ferrous sulphate on haemoglobin concentration and serum ferritin concentration after 12 weeks of supplementation. Methods: This will be a two-arm, randomised controlled trial. Gambian children aged 6-12 months with anaemia will be recruited within a predefined geographical area and recruited by trained field workers. Eligible participants will be individually randomised using a 1:1 ratio within permuted blocks to daily supplementation for 12 weeks with either 10.0mg of elemental iron as haem or ferrous sulphate. Safety outcomes such as diarrhoea and infection-related adverse events will be assessed daily by the clinical team. Linear regression will be used to analyse continuous outcomes, with logtransformation to normalise residuals as needed. Binary outcomes will be analysed by binomial regression or logistic regression, Primary analysis will be by modified intention-to-treat (i.e., those randomised and who ingested at least one supplement dose of iron), with multiple imputations to replace missing data. Effect estimates will be adjusted for baseline covariates (C-reactive protein, alpha-1-acid glycoprotein, haemoglobin, ferritin, soluble transferrin receptor) Discussion: This study will determine if therapeutic supplementation with haem iron is more efficacious than with conventional ferrous sulphate in enhancing haemoglobin and ferritin concentrations in anaemic children aged 6-12 months.
Boletín médico del Hospital Infantil de México, 2022
Background: Iron deficiency prevalence in infants is high. Therefore, iron supplementation has been recommended and specified as a program. This study aimed to determine the characteristics of the prescription of ferrous sulfate as a preventive therapy for iron deficiency anemia in young infants. Methods: We conducted a descriptive cross-sectional study of clinical records of young infants with eight visits per year. We analyzed a total of 287 records. The prescription characteristics included five criteria: prescription indication, age at prescription, dosage, periodicity, and time. These characteristics were scored as follows: 1 point when it was considered adequate and 0 when it was considered inadequate; the minimum possible score was 0, and the maximum possible score was 5 points. Statistical analysis included percentages and 95% confidence intervals (CI). Results: The prescription pattern of ferrous sulfate as preventive therapy in infants under one year of age was indicated in 100% of the records reviewed. All five criteria were met in 18.1% of the reviewed records (95%CI 13.6-22.6). The lowest compliance corresponded to adequate dosage (29.2%; 95%CI 23.9-34.5). Age at prescription was correct in 75.9% (95%CI 70.9-80.9); duration of prescription was correct in 44.2% (95%CI 38.4-50.0), and periodicity was proper in 31.1% (95%CI 25.9-36.7) of the files reviewed. Conclusions: Compliance with the prescription of ferrous sulfate as a preventive measure for anemia in infants was not as expected; interventions are needed to reverse this behavior.
Journal of Applied Pharmaceutical Science, 2015
To compare the efficacy and safety of different oral and parenteral iron preparations in patients with anemia. Methods: An observational, prospective study in patients of anemia in pregnancy and chronic kidney disease (CKD) receiving iron sucrose, oral ferrous ascorbate and ferrous sulfate were included. Demographic details, clinical history, baseline hemoglobin, anemia indices data were recorded in a case record form. The patients were followed up monthly for 12 weeks and observed for clinical and haematological improvement and adverse drug reactions (ADRs). The data was analyzed using paired t-test, unpaired t-test and Fisher`s exact test. Results: Out of 232 patients, 84 received iron sucrose, 62 ferrous ascorbate and 86 ferrous sulfate. Oral and parenteral iron preparations significantly (P<0.0001) improved mean hemoglobin, anemia indices and serum ferritin at the end of study. However, mean increase in hemoglobin and anemia indices were significant (P<0.0001) with iron sucrose (4.42 ± 0.17gms/dL) as compared to ferrous ascorbate (3.45 ± 0.1) and sulfate (3.3 ± 0.4). Increase in serum ferritin was more and rapid (at 4 weeks) with iron sucrose as compared to ferrous ascorbate in CKD patients. Surprisingly, ADRs were more in patients treated with oral ferrous sulfate (86%) and ascorbate (71%) compared to iron sucrose (63%). Conclusion: Parenteral iron sucrose improves hemoglobin. anemia indices and replenish iron stores rapidly and is well tolerated than oral iron preparations.